• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home 2 Minute Medicine

Spinal cord stimulation shows considerable improvement in pain and quality of life for patients with refractory diabetic neuropathy

byYuchen DaiandMichael Pratte
June 2, 2021
in 2 Minute Medicine, Chronic Disease, Endocrinology, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. 10-kHz spinal cord stimulation (SCS) was safe and effective in treating patients with painful diabetic neuropathy (PDN) refractory to medical management, leading to substantial pain relief and improved health-related quality of life over 6 months.

2. In practice, these results support the integration of 10-kHz SCS into the evidence-based clinical treatment guidelines and continuum of care for patients with PDN refractory to conventional medical management (CMM).

Evidence Rating Level: 1 (Excellent)

Study Rundown: Diabetes has been known to cause systemic changes resulting in profound negative impacts on health and overall quality of life for patients. If left untreated, it can lead to potentially life-threatening complications. Diabetic peripheral neuropathy is a common complication presenting as refractory pain and other dysesthesias. Approximately 20% of patients with diabetes will develop PDN, a progressive and potentially debilitating chronic neuropathic pain condition. Current treatments for PDN include neuropathic pain medications, such as gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, opioids, and topical solutions. However, high-quality randomized controlled trials (RCT) have demonstrated limited efficacy of these medications with high incidence of adverse effects. Nonpharmacological treatment for PDN with SCS devices was first used in 1996 and studies since have supported 10-kHz (high-frequency) SCS as a superior treatment for chronic, neuropathic pain compared to low-frequency SCS. This prospective, multicenter RCT, SENZA-PDN, compared CMM with 10-kHz SCS plus CMM in patients with PDN refractory to best available medical treatments. Using the inclusion and exclusion criteria, 216 patients with refractory PDN were randomized including 103 assigned to the CMM control group and 113 assigned to the 10-kHz SCS plus CMM treatment group. In the CMM group, 5 of 94 patients (5%) met the prespecified primary end point of 50% or more pain relief assessed via visual analogue scale (VAS) without observed deterioration on neurological examination, compared with 75 of 95 patients in the 10-kHz SCS plus CMM group (79%). This highlights the substantial pain relief and improved health-related quality of life sustained over 6 months in patients with refractory PDN treated with 10-kHz SCS. A major limitation of this study, however, was the lack of blinding between treatment groups as comparing an implantable medical device with best available medical treatment made this extremely difficult. This may have influenced patients and investigators leading to potential biases and placebo effects.

Click to read the study in JAMA

Relevant Reading: Spinal Cord Stimulation and Pain Relief in Painful Diabetic Peripheral Neuropathy: A Prospective Two-Center Randomized Controlled Trial

In-Depth [randomized controlled trial]: This prospective, multicenter RCT took place across 18 treatment sites in the United States between 2017 and 2019. Key inclusion criteria included a diagnosis of PDN with symptoms for 12 months or more refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic and lower limb pain of 5 cm or more on a 10-cm VAS. Initial screening of 430 candidates resulted in 216 patients with PDN who were randomized. Of these, 103 were assigned to CMM and 113 assigned to 10-kHz SCS plus CMM. The mean (SD) age was 60.8 (10.7) years, 136 (63.0%) were male, and the median (interquartile range) duration of diabetes and peripheral neuropathy were 10.9 (6.3-16.4) years and 5.6 (3.0-10.1) years, respectively. Accounting for patients lost to follow-up and adverse events (infection from device implant, 2%), the primary end point assessed in the intention-to-treat population was met by 5 of 94 patients in the CMM control group (5%) and 75 of 95 patients in the 10-kHz SCS plus CMM group (79%; difference, 73.6%; 95% CI, 64.2-83.0; P<0.001). For the study’s secondary end point assessments, the mean pain VAS score was 7.0 cm (95% CI, 6.7-7.3) at baseline and 6.9 cm (95% CI, 6.5-7.3) at 6 months for the CMM group. For the 10-kHz SCS plus CMM group, the mean pain VAS score was 7.6 cm (95%CI, 7.3-7.9) at baseline and 1.7 cm (95%CI, 1.3-2.1) at 6 months. Furthermore, improvements from baseline without any worsening on neurological examination was observed in 3 of 92 patients in the CMM group (3%) and 52 of 84 in the 10-kHz SCS plus CMM group (62%) at 6 months (difference, 58.6%; 95%CI, 47.6-69.6; P<0.001).

RELATED REPORTS

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

The Scan by 2 Minute Medicine®: Black History Month, Mr.Beast, Damar Hamlin and on-field CPR, Ozempic Shortage

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetesDiabetic Neuropathiesneuropathyspinal cord stimulation
Previous Post

No association found between 9-valent Human Papillomavirus Vaccine during pregnancy and adverse pregnancy outcomes

Next Post

3 days of β-lactam therapy is non-inferior to 8 days of therapy among patients with community-acquired pneumonia

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

March 21, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

March 7, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Black History Month, Mr.Beast, Damar Hamlin and on-field CPR, Ozempic Shortage

March 14, 2023
Prescription of antibiotics for acute respiratory infections increasing
Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of respiratory events in Type 2 diabetics

February 16, 2023
Next Post
Prescription of antibiotics for acute respiratory infections increasing

3 days of β-lactam therapy is non-inferior to 8 days of therapy among patients with community-acquired pneumonia

#VisualAbstract: Azithromycin does not improve clinical outcomes in high-risk patients with suspected COVID-19 in the community setting

#VisualAbstract: Azithromycin does not improve clinical outcomes in high-risk patients with suspected COVID-19 in the community setting

Lessons from real-world implementation of lung cancer screening

Tislelizumab plus chemotherapy vs chemotherapy alone as treatment for advanced squamous NSCLC

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Active surveillance strategies to improve rates of inferior vena cava filter retrieval
  • Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response
  • Hydrochlorothiazide does not impact risk of kidney-stone recurrence
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options